Lin Dongdong, Wang Ming, Chen Yan, Gong Jie, Chen Liang, Shi Xiaoyong, Lan Fujun, Chen Zhongliang, Xiong Tao, Sun Hu, Wan Shu
Brain Center, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Oncol. 2021 Nov 1;11:748061. doi: 10.3389/fonc.2021.748061. eCollection 2021.
Glioma incidence in the US seems to have stabilized over the past 20 years. It's also not clear whether changes in glioblastoma incidence are associated with glioma mortality trends. Our study investigated trends in glioma incidence and mortality according to tumor characteristics.
This study obtained data from the Surveillance, Epidemiology, and End Results-9 (SEER-9) registries to calculate glioma incidence and mortality trends. Annual percent changes (APC) and 95% CIs were calculated using the Joinpoint program.
62,159 patients (34,996 males and 55,424 whites) were diagnosed with glioma during 1975-2018, and 31,922 deaths occurred from 1995-2018. Glioblastoma (32,893 cases) and non-glioblastoma astrocytoma (17,406 cases) were the most common histologic types. During the study period, the incidence of glioma first experienced a significant increase (APC=1.8%, [95% CI, 1.3% to 2.3%]) from 1975 to 1987, and then experienced a slight decrease (APC=-0.4%, [95% CI, -0.5% to -0.3%]) from 1987 to 2018, while the APC was 0.8% for glioblastoma, -2.0% for non-glioblastoma astrocytoma, 1.1% for oligodendroglial tumors, 0.7% for ependymoma and -0.3% for glioma NOS during the study period. Glioblastoma incidence increased for all tumor size and tumor extension except for distant. From 1995 to 2018, glioma mortality declined 0.4% per year (95% CI: -0.6% to -0.2%) but only increased in patients older than 80 years [APC=1.0%, (95% CI, 0.4% to 1.6%)].
Significant decline in glioma incidence (1987-2018) and mortality (1995-2018) were observed. Epidemiological changes in non-glioblastoma astrocytoma contributed the most to overall trends in glioma incidence and mortality. These findings can improve understanding of risk factors and guide the focus of glioma therapy.
在过去20年中,美国神经胶质瘤的发病率似乎已趋于稳定。胶质母细胞瘤发病率的变化是否与神经胶质瘤死亡率趋势相关也尚不清楚。我们的研究根据肿瘤特征调查了神经胶质瘤的发病率和死亡率趋势。
本研究从监测、流行病学和最终结果-9(SEER-9)登记处获取数据,以计算神经胶质瘤的发病率和死亡率趋势。使用Joinpoint程序计算年度百分比变化(APC)和95%置信区间(CI)。
1975年至2018年期间,62159例患者(34996例男性和55424例白人)被诊断为神经胶质瘤,1995年至2018年期间有31922例死亡。胶质母细胞瘤(32893例)和非胶质母细胞瘤星形细胞瘤(17406例)是最常见的组织学类型。在研究期间,神经胶质瘤的发病率首先在1975年至1987年期间显著上升(APC=1.8%,[95%CI,1.3%至2.3%]),然后在1987年至2018年期间略有下降(APC=-0.4%,[95%CI,-0.5%至-0.3%]),而研究期间胶质母细胞瘤的APC为0.8%,非胶质母细胞瘤星形细胞瘤为-2.0%,少突胶质细胞瘤为1.1%,室管膜瘤为0.7%,未特指的神经胶质瘤为-0.3%。除远处转移外,所有肿瘤大小和肿瘤扩展的胶质母细胞瘤发病率均有所上升。1995年至2018年,神经胶质瘤死亡率每年下降0.4%(95%CI:-0.6%至-0.2%),但仅在80岁以上患者中有所上升[APC=1.0%,(95%CI,0.4%至1.6%)]。
观察到神经胶质瘤发病率(1987 - 2018年)和死亡率(1995 - 2018年)显著下降。非胶质母细胞瘤星形细胞瘤的流行病学变化对神经胶质瘤发病率和死亡率的总体趋势贡献最大。这些发现有助于提高对危险因素的认识,并指导神经胶质瘤治疗的重点。